Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event

Inclusion Criteria: * The patient has a high risk of a cardiovascular event as defined by the European guidelines. * The patient is statin-naive (i.e. has not used a statin \> 2 months), or is currently treated with atorvastatin, pravastatin or simvastatin. * An LDL-C level is known for the statin-naive patient or for the statin used during visit 1. * It has been decided to start the patient on CRESTOR 5 mg. * The patient is prepared to give permission to the coded data being made available to AstraZeneca Exclusion Criteria: * The patient is known to have complaints of myalgia, myopathy or liver function impairment (including elevated levels of serum transaminases) where there is a causal relationship with the statin treatment. * Contraindications for treatment with CRESTOR (see 1 B1 text). * Patients with a family history of dyslipidemias, for instance familiar (combined) hypercholesterolemia